We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $58.68, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.52%, while the tech-heavy Nasdaq depreciated by 0.08%.
Shares of the drugmaker witnessed a gain of 9.64% over the previous month, beating the performance of the Medical sector with its gain of 3.31%, and the S&P 500's gain of 4.03%.
Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 5, 2025. The company's earnings per share (EPS) are projected to be $0.8, reflecting a 11.11% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.88 billion, indicating a 13.12% increase compared to the same quarter of the previous year.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.68 per share and revenue of $48.73 billion. These results would represent year-over-year changes of +12.2% and +15.77%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novo Nordisk. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.62% lower. At present, Novo Nordisk boasts a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Novo Nordisk is currently being traded at a Forward P/E ratio of 16.21. This signifies a premium in comparison to the average Forward P/E of 14.65 for its industry.
Meanwhile, NVO's PEG ratio is currently 2.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. NVO's industry had an average PEG ratio of 1.59 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $58.68, marking a -1.56% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.52%, while the tech-heavy Nasdaq depreciated by 0.08%.
Shares of the drugmaker witnessed a gain of 9.64% over the previous month, beating the performance of the Medical sector with its gain of 3.31%, and the S&P 500's gain of 4.03%.
Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 5, 2025. The company's earnings per share (EPS) are projected to be $0.8, reflecting a 11.11% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.88 billion, indicating a 13.12% increase compared to the same quarter of the previous year.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.68 per share and revenue of $48.73 billion. These results would represent year-over-year changes of +12.2% and +15.77%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novo Nordisk. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.62% lower. At present, Novo Nordisk boasts a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Novo Nordisk is currently being traded at a Forward P/E ratio of 16.21. This signifies a premium in comparison to the average Forward P/E of 14.65 for its industry.
Meanwhile, NVO's PEG ratio is currently 2.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. NVO's industry had an average PEG ratio of 1.59 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.